Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FINANCE ROUNDUP: A New VC Fund, A $60m Collaboration Boost, And 14 Funding Rounds

This article was originally published in Scrip

Executive Summary

Private investment in biotechnology companies continues to churn out startups and support the next stage of drug development for established early-stage firms, despite the rollercoaster rise and fall of public biotech company valuations, with venture capital firms continuing to raise money for new funds and invest the proceeds in new opportunities.

Advertisement

Related Content

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs
BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back

Topics

Advertisement
UsernamePublicRestriction

Register

SC063742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel